Sigolène Galland-Girodet1, Jean-Philippe Maire2, Erwan De-Mones3, Julie Benech4, Kheireddine Bouhoreira4, Benoit Protat4, Hélène Demeaux4, Vincent Darrouzet5, Aymeri Huchet4. 1. Univ. de Bordeaux, France; CHU de Bordeaux, Department of Radiation Oncology, France; Massachusetts General Hospital, Department of Radiation Oncology, Harvard Medical School, Boston, USA. Electronic address: dr.sgalland@bordeauxnord.com. 2. Univ. de Bordeaux, France; CHU de Bordeaux, Department of Radiation Oncology, France. 3. CHU de Bordeaux, Department of Oto-Rhino-Laryngology and Skull Base Surgery, France. 4. CHU de Bordeaux, Department of Radiation Oncology, France. 5. Univ. de Bordeaux, France; CHU de Bordeaux, Department of Oto-Rhino-Laryngology and Skull Base Surgery, France.
Abstract
PURPOSE: To assess the impact of radiotherapy in paragangliomas (PGLs) with regard to overall survival, local control, volumetric response and particularly quality of life (QoL). MATERIALS AND METHODS: From 1985 to 2010, 130 cases of head and neck (H&N) PGLs were managed at Bordeaux University Hospital. With a median follow-up of 7.6 years, we retrospectively present a cohort of 30 consecutive patients treated with radiation therapy for H&N PGLs. QoL was evaluated for 20 patients by the EORTC QLQ-C30 and H&N35 questionnaires through a cross-sectional study. RESULTS: The 5-year overall survival and local control were 95% and 96% respectively. QoL is altered following management of PGLs. The H&N35 score is lower after combined modality therapy (surgery±embolization and radiation therapy) for speech and hearing (p=0.004), trismus (p=0.003) and total score (p=0.01) than after radiotherapy alone. Tumor shrinkage was significant at 2 and 3 years after radiotherapy (p=0.018; p=0.043). CONCLUSION: Ultimate QoL should be a major goal of any treatment strategy for this benign disease. Definitive radiotherapy should be considered as a reasonable alternative to multimodality treatment as it provides comparable disease control with an apparent improvement in QoL.
PURPOSE: To assess the impact of radiotherapy in paragangliomas (PGLs) with regard to overall survival, local control, volumetric response and particularly quality of life (QoL). MATERIALS AND METHODS: From 1985 to 2010, 130 cases of head and neck (H&N) PGLs were managed at Bordeaux University Hospital. With a median follow-up of 7.6 years, we retrospectively present a cohort of 30 consecutive patients treated with radiation therapy for H&N PGLs. QoL was evaluated for 20 patients by the EORTC QLQ-C30 and H&N35 questionnaires through a cross-sectional study. RESULTS: The 5-year overall survival and local control were 95% and 96% respectively. QoL is altered following management of PGLs. The H&N35 score is lower after combined modality therapy (surgery±embolization and radiation therapy) for speech and hearing (p=0.004), trismus (p=0.003) and total score (p=0.01) than after radiotherapy alone. Tumor shrinkage was significant at 2 and 3 years after radiotherapy (p=0.018; p=0.043). CONCLUSION: Ultimate QoL should be a major goal of any treatment strategy for this benign disease. Definitive radiotherapy should be considered as a reasonable alternative to multimodality treatment as it provides comparable disease control with an apparent improvement in QoL.
Authors: Matthew L Bush; Mitchell R Dobberpuhl; Stevie Maxwell; Jonathan Feddock; William St Clair Journal: Otol Neurotol Date: 2017-08 Impact factor: 2.311